Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals reports developments around its transition into precision diagnostics, with a focus on blood-based tests for hepatocellular carcinoma and other disease areas. Company updates include the ctRNA biomarker assay licensed for early diagnosis and surveillance of HCC, the mSEPT9 PCR-based assay for liver cancer detection, and diagnostic test categories covering celiac disease, respiratory multiplex testing, H. pylori, and HCC.
Hepion news also covers public-company status changes and capital actions, including OTCQB trading, reverse stock split activity, Nasdaq delisting developments, leadership changes, stockholder voting matters, and the completed sale of rencofilstat-related patent assets, knowhow, clinical trial data, and drug product.
Hepion Pharmaceuticals (NASDAQ:HEPA) has announced the launch of AI-POWR™, a proprietary AI and machine learning platform aimed at improving drug development for non-alcoholic steatohepatitis (NASH). AI-POWR™ utilizes a multi-omics approach to enhance patient selection and optimize clinical trial outcomes for Hepion's lead drug candidate, CRV431, which is currently in a Phase 2a trial. The initiative is expected to reduce costs and development timelines while enhancing the likelihood of clinical success.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that CEO Dr. Robert Foster will present virtually at the H.C. Wainwright 4th Annual NASH Conference on October 5, 2020, at 4:00 p.m. E.T. The presentation will be accessible live and archived on the company’s website under the 'Events' section. Hepion focuses on developing therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH). Its lead candidate, CRV431, targets liver fibrosis and exhibits antiviral properties, showcasing potential in treating various liver diseases.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive findings from a study by the National Institute of Allergy and Infectious Diseases (NIAID), showing that its drug candidate CRV431 exhibits significant antiviral activity against SARS-CoV-2. The study found CRV431 inhibited viral production with an IC90 of 1.5 μM, nearly five times more potent than a control compound. No significant cellular toxicity was observed. Hepion aims to advance CRV431 through further studies while maintaining focus on its current phase 2a program for NASH.
Hepion Pharmaceuticals announced the completion of CRV431 dosing in all subjects for its Phase 1b multiple ascending dose study. This study aimed to evaluate the safety, tolerability, and pharmacokinetics of CRV431, with doses ranging from 75 mg to 375 mg administered to healthy volunteers. The drug was well tolerated at all levels. Hepion is advancing to its Phase 2a AMBITION trial, expecting to complete the 75 mg dosing by the end of 2020. The study's outcomes are vital for further drug development targeting liver diseases like NASH.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced it will present a poster on CRV431's antifibrotic activity at the Digital International Liver Congress™ 2020 from August 27-29. Dr. Joseph Kuo will discuss a preclinical study highlighting CRV431's ability to reduce hepatic fibrosis and weight gain in a NASH mouse model. The presentation is scheduled for August 28, 2020, under poster number FRI-239. Hepion aims to develop targeted therapies for liver diseases, with CRV431 showing promise in reducing fibrosis and hepatocellular carcinoma tumor burden.
Hepion Pharmaceuticals announced a study published in PLOS ONE demonstrating that its lead drug candidate, CRV431, effectively inhibits hepatitis C virus (HCV) infection in a humanized liver mouse model. The study showed that CRV431 administration resulted in complete suppression of HCV replication with no viral rebound observed five months post-treatment. The findings highlight CRV431's potential utility against various viral infections, including COVID-19. Hepion is advancing CRV431 through a Phase 2a clinical trial for NASH.
Hepion Pharmaceuticals announced that a peer-reviewed study published in PLOS ONE demonstrated that CRV431, its leading drug candidate, effectively inhibited hepatitis C virus (HCV) infection in a humanized liver mouse model with no observed viral rebound after five months. This study supports CRV431's antiviral potential and adds to existing data indicating its efficacy against multiple viral infections, including hepatitis B and HIV. The drug is currently in a Phase 2a clinical trial for treating liver disease due to NASH.